Direct healthcare costs associated with sickle cell disease complications: a retrospective cohort study using routinely collected healthcare data in England
Estimating the cost of complications, while accounting for multimorbidity, is essential to determine the true direct cost of SCD. The modelling method presented in our study provides period-based estimates of cost and hospital admissions for individual complications in patients with SCD, accounting for multimorbidity. This approach can be used and extended to other diseases with multisystemic complications to estimate the direct HCRU and costs of individual complications.
Authors
- S João Carvalho
- Lili Jiang (ORCID: https://orcid.org/0000-0003-1628-7248)
- Giovanna Tedesco Barcelos (ORCID: https://orcid.org/0009-0009-1756-1190)
- Caoimhe Rice (ORCID: https://orcid.org/0000-0003-3017-2279)
- R. Wirz
- Martin Besser (ORCID: https://orcid.org/0000-0003-1004-6232)
- Anna Filonenko (ORCID: https://orcid.org/0000-0003-4553-0534)
- Jennifer Davidson (ORCID: https://orcid.org/0000-0003-1599-7504)
- Paul Telfer
Institutions
- Queen Mary University of London (GB)
- Pfizer (United States) (US)
- Pfizer (Switzerland) (CH)
- Pfizer (Germany) (DE)
- Cheshire West and Chester (GB)
- Addenbrooke's Hospital (GB)
Publication Details
- Journal
- BMJ Open
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1136/bmjopen-2025-106082
- Primary Topic
- Hemoglobinopathies and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00